These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
465 related articles for article (PubMed ID: 28032528)
1. Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer: still hope after the last hope? Bertocchi P; Aroldi F; Prochilo T; Meriggi F; Beretta GD; Zaniboni A J Chemother; 2017 Apr; 29(2):102-105. PubMed ID: 28032528 [TBL] [Abstract][Full Text] [Related]
2. Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer. Kim ST; Choi YJ; Park KH; Oh SC; Seo JH; Shin SW; Kim JS; Kim YH Asia Pac J Clin Oncol; 2011 Mar; 7(1):82-7. PubMed ID: 21332655 [TBL] [Abstract][Full Text] [Related]
3. Analyses of multiple factors for determination of "selected patients" who should receive rechallenge treatment in metastatic colorectal cancer: a retrospective study from Turkey. Ozaslan E; Duran AO; Bozkurt O; Inanc M; Ucar M; Berk V; Karaca H; Elmali F; Ozkan M Asian Pac J Cancer Prev; 2015; 16(7):2833-8. PubMed ID: 25854370 [TBL] [Abstract][Full Text] [Related]
4. Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer? Köstek O; Hacıoğlu MB; Sakin A; Demir T; Sarı M; Ozkul O; Araz M; Doğan AF; Demircan NC; Uzunoğlu S; Çiçin İ; Erdoğan B Cancer Chemother Pharmacol; 2019 Jan; 83(1):115-122. PubMed ID: 30374523 [TBL] [Abstract][Full Text] [Related]
5. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial). García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E; Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161 [TBL] [Abstract][Full Text] [Related]
6. Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen. Fornaro L; Vasile E; Masi G; Loupakis F; Baldi GG; Allegrini G; Salvatore L; Cremolini C; Cupini S; Cortesi E; Tuzi A; Granetto C; Brunetti IM; Ricci S; Falcone A Clin Colorectal Cancer; 2012 Mar; 11(1):71-6. PubMed ID: 21903485 [TBL] [Abstract][Full Text] [Related]
7. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer. Hecht JR; Cohn A; Dakhil S; Saleh M; Piperdi B; Cline-Burkhardt M; Tian Y; Go WY Clin Colorectal Cancer; 2015 Jun; 14(2):72-80. PubMed ID: 25982297 [TBL] [Abstract][Full Text] [Related]
8. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study. Bennouna J; Borg C; Delord JP; Husseini F; Trillet-Lenoir V; Faroux R; François E; Ychou M; Goldwasser F; Bouché O; Senellart H; Kraemer S; Douillard JY Clin Colorectal Cancer; 2012 Mar; 11(1):38-44. PubMed ID: 21803002 [TBL] [Abstract][Full Text] [Related]
9. [KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer]. Cabart M; Frénel JS; Campion L; Ramée JF; Dupuis O; Senellart H; Hiret S; Douillard JY; Bennouna J Bull Cancer; 2016 Jun; 103(6):541-51. PubMed ID: 27155924 [TBL] [Abstract][Full Text] [Related]
10. Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer. Tai CC; Chen WS; Jiang JK; Yang SH; Wang HS; Chang SC; Lan YT; Lin CC; Lin HH; Huang SC; Cheng HH; Chao Y; Teng HW Am J Clin Oncol; 2020 Jan; 43(1):28-34. PubMed ID: 31693507 [TBL] [Abstract][Full Text] [Related]
11. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study. Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama C; Denda T; Satake H; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Sugiyama M; Komatsu Y; Okuyama H; Baba E; Sakai D; Watanabe T; Tamura T; Yamashita K; Gosho M; Shimada Y Oncologist; 2018 Jan; 23(1):7-15. PubMed ID: 28894015 [TBL] [Abstract][Full Text] [Related]
12. The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent. Scicinski J; Fisher G; Carter C; Cho-Phan C; Kunz P; Ning S; Knox S; Oronsky B; Caroen S; Parker C; Fanger G; Reid T Redox Biol; 2015 Aug; 5():422. PubMed ID: 28162292 [TBL] [Abstract][Full Text] [Related]
13. Capecitabine plus temozolomide (CapTem): An alternative regimen to regorafenib as third-line setting in metastatic colorectal cancer? Ergun Y; Bal O; Dogan M; Uncu D J BUON; 2019; 24(6):2435-2441. PubMed ID: 31983117 [TBL] [Abstract][Full Text] [Related]
14. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801). Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C Oncology; 2014; 87(1):7-20. PubMed ID: 24968756 [TBL] [Abstract][Full Text] [Related]
15. Changes in CT morphology can be an independent response marker for patients receiving regorafenib for colorectal liver metastases: retrospective pilot study. Ozaki Y; Shindoh J; Gonoi W; Nishioka Y; Kondoh C; Tanabe Y; Matoba S; Kuroyanagi H; Hashimoto M; Takano T BMC Cancer; 2018 Feb; 18(1):138. PubMed ID: 29402244 [TBL] [Abstract][Full Text] [Related]
16. FOLFIRINOX bevacizumab is a promising therapy for chemorefractory metastatic colorectal cancer. Chaix M; Vincent J; Lorgis V; Ghiringhelli F Oncology; 2014; 87(3):148-58. PubMed ID: 25012455 [TBL] [Abstract][Full Text] [Related]
17. Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer. Larsen FO; Pfeiffer P; Nielsen D; Skougaard K; Qvortrup C; Vistisen K; Fromm AL; Jørgensen TL; Bjerregaard JK; Hoegdall E; Jensen BV Acta Oncol; 2011 May; 50(4):574-7. PubMed ID: 21529301 [TBL] [Abstract][Full Text] [Related]
18. A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy. Nielsen DL; Palshof JA; Larsen FO; Jensen BV; Pfeiffer P Cancer Treat Rev; 2014 Jul; 40(6):701-15. PubMed ID: 24731471 [TBL] [Abstract][Full Text] [Related]
19. [Recent results of irinotecan therapy in colorectal cancer]. Láng I; Hitre E Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572 [TBL] [Abstract][Full Text] [Related]
20. Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib. Unseld M; Drimmel M; Siebenhüner A; Gleiss A; Bianconi D; Kieler M; Scheithauer W; Winder T; Prager GW Clin Colorectal Cancer; 2018 Dec; 17(4):274-279. PubMed ID: 30042010 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]